According to Humphrey and colleagues, one-third of patients with intravenous insulin-dextrose (IDex) for hyperkalemia needed repeated treatments with IDex [1]. Besides, approximately 20% of patients who underwent IDex developed hypoglycemia with a serum glucose level <4 mmol/L. Thus, the authors concluded that physicians should monitor serum glucose levels after IDex treatment. This study focused on the sequential changes in serum potassium and glucose levels and seemed helpful in actual clinical settings.
